Recombinant vascular endothelial growth factor 121 decreases vascular cell adhesion molecule-1 in murine pre-eclampsia model placenta
Article Sidebar
Main Article Content
Abstract
Preeclampsia is one of the major contributors to maternal and fetal morbidity and mortality. Imbalance of soluble Fms-like tyrosine kinase (sFlt-1) as anti-angiogenic factor and vascular endothelial growth factor (VEGF) as pro-angiogenic factor plays a role in the pathogenesis of preeclampsia. Endothelial dysfunction in preeclampsia causes vascular cell adhesion molecule-1 (VCAM-1) to be expressed on its surface. This study aims to evaluate the effect of recombinant VEGF-121 on VCAM-1 expression in the placenta of a murine preeclampsia model.
Methods
An experimental analytical study conducted from February until March 2016 in the Biomedical Laboratory, Faculty of Veterinary Medicine, Airlangga University. The study sample consisted of 30 pregnant mice, divided into three groups, i.e. 10 normal pregnant mice, 10 mice with preeclampsia model and 10 mice with preeclampsia model and recombinant VEGF-121 therapy. All animals were subjected to immunohistochemical examination of VCAM-1 expression in their placentas. The results were assessed semiquantitatively according to a modified Remmele method. Data analysis was done using one-way ANOVA and Tukey’s multiple comparisons method.
Results
Mean VCAM-1 expression in normal (0.97 ± 0.54%) murine placentas, compared with placentas (2.94 ± 0.96%) of murine preeclampsia models (p=0.000), while mean VCAM-1 expression in placentas of murine preeclampsia models with VEGF intervention was 2.14 ± 0.68% (p=0.030).
Conclusion
Recombinant VEGF-121 can reduce VCAM-1 expression in placentas of murine preeclampsia models. The present study has shown the potential benefits of VEGF therapy, justifying serious consideration of this therapeutic approach for use in women with preeclampsia.
Article Details
The journal allows the authors to hold the copyright without restrictions and allow the authors to retain publishing rights without restrictions.
References
Osungbade KO, Ige OK. Public health perspectives of preeclampsia in developing countries: implication for health system strengthening. J Pregnancy 2011; Article ID 481095, 6 pages. http://dx.doi.org/10.1155/2011/481095.
Kooffreh ME, EkottM, Ekpoudom DO. The prevalence of pre-eclampsia among pregnant women in the University of Calabar Teaching Hospital, Calabar. Saudi J Health Sci 2014;3: 133-6.
Maynard SE, Karumanchi SA. Angiogenic factors and preeclampsia. Semin Nephrol 2011; 31:33-46.
Sulistyowati S, Soetrisno, Kartika NH. Ekspresi human leukocyte antigen–C di trofoblas dan natural killer cell di desidua pada preeklampsia berat. Jurnal Kedokteran Brawijaya 2016;29:59-63.
Roberts CL, Ford JB, Algert CS, et al. Population-based trends in pregnancy hypertension and pre-eclampsia: an international comparative study. BMJ Open 2011;24:e000101. doi: 10.1136/bmjopen-2011-000101.
Aabidha PM, Cherian AG, Paul E, et al. Maternal and fetal outcome in pre-eclampsia in a secondary care hospital in South India. J Family Med Prim Care 2015;4:257–60.
Woods AK, Hoffmann DS, Weydert CJ, et al. Adenoviral delivery of VEGF 121 early in pregnancy prevents spontaneous development of pre-eclampsia in BPH/5 mice. Hypertension 2011;57:94-102.
Roberts JM, Hubel CA. The two stage model of preeclampsia: variation on the theme. Placenta 2009;30 Suppl A:S32-7.
Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355: 992-1005.
Gu Y, Lewis DF, Wang Y. Placental productions and expressions of soluble fms-like tyrosine, soluble endoglin, and placental growth factor in normal and preeclamptic pregnancies. J Clin Endocrinol Metab 2008;93:260-6.
Zeisler H, Llurba E, Chantraine F, et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med 2016;374:13-22. DOI: 10.1056/NEJMoa 1414838.
Warrington JP, George EM, Palei AC, et al. Recent advances in the understanding of the pathophysiology of preeclampsia. Hypertension 2013;62:666-73.
Sulistyowati S, Abadi A, Hood J, et al. The influence of low HLA-G protein expression on HSP-70 and VCAM-1 profile in preeclampsia. Indonesian J Obstet Gynecol 2010;34:185–90.
Sulistyowati S, Abadi A, Wijiati M. Low class Ib (HLA-G/Qa2) MHC protein expression against HSP-70 and VCAM-1 profile on preeclampsia: an observation on experimental animal Mus musculus with endothelial dysfunction model. Indonesian J Obstet Gynecol 2010;34:103–6.
Li Z, Zhang Y, Ying Ma J, et al. Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension 2007;50:686-92.
Mateus J, Bytautiene E, Lu F, et al. Endothelial growth factor therapy improves preeclampsia-like manifestasions in a murine model induced by overexpression of sVEGFR-1. Am J Physiol Heart Circ Physiol 2011;301:H1781-7.
Steel RG, Torrie JH, Dickey DA. Principles and procedures of statistics: a biometrical approach. 3rd ed. New York: McGraw-Hill Companies; 1997.
Halon A, Donizy P, Biecek P, et al. HER-2 expression in immunohistochemistry has no prognostic significance in gastric cancer patients. Sci World J 2012; Article ID 941259, 6 pages. DOI: 10.1100/2012/941259.
Anwar AD, Achmad TH, Krisnadi SR, et al. Polimorfisme C1167T gen reseptor tipe II transforming growth factor-â, kadar soluble endoglin dan vascular adhesion molecule-1 pada preeklamsia. MKB 2010;42:115-22.
Bergmann A, Ahmad S, Cudmore M, et al. Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model. J Cell Mol Med 2001;14:1857-67.
Gilbert JS, Verzwyvelt J, Colson D, et al. Recombinant VEGF121 infusion lowers blood pressure and improves renal function in rats with placental ischemia-induced hypertension. Hypertension 2010;55:380-5.
Agarwal I, Karumanchi SA. Preeclampsia and the anti-angiogenic state. Pregnancy Hypertens 2011;1:17-21.